CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense ...
Researchers describe minimal versatile genetic perturbation technology (mvGPT). Capable of precisely editing genes, activating gene expression and repressing genes all at the same time, the technology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback